Intracranial meningiomas: II. Diagnosis and treatment.

06:00 EDT 23rd July 2011 | BioPortfolio

Summary of "Intracranial meningiomas: II. Diagnosis and treatment."

INTRODUCTION. Meningiomas are the most frequent group of intracranial tumours. In most cases, they are histologically benign tumours, although the fact that they may be located in anatomical areas that are difficult to reach with surgical techniques often means that their treatment must be complemented with oncological therapies. AIMS. To update our current knowledge about the diagnostic techniques and therapeutic options available for intracranial meningiomas, so as to have the latest information on this subject. DEVELOPMENT. The study involves a review of the literature that covers aspects related to the different complementary diagnostic techniques and the alternative methods of treatment. CONCLUSIONS. Magnetic resonance imaging, in all its different sequences, is the preferred diagnostic technique, since it allows 100% intracranial meningiomas to be diagnosed. Although surgery is the preferred treatment technique in most cases, radiotherapy, in its different modes, is an essential therapeutic tool, both as a complement to surgery and as the first choice.


Hospital Clinico de Santiago de Compostela, 15706 Santiago de Compostela, Espana.

Journal Details

This article was published in the following journal.

Name: Revista de neurologia
ISSN: 1576-6578
Pages: 226-32


DeepDyve research library

PubMed Articles [24405 Associated PubMed Articles listed on BioPortfolio]

EANO guidelines for the diagnosis and treatment of meningiomas.

Although meningiomas are the most common intracranial tumours, the level of evidence to provide recommendations for the diagnosis and treatment of meningiomas is low compared with other tumours such a...

Prognosis of meningiomas in the early 1970s and today.

The benefit of the current strategy of diagnosis and treatment of meningiomas in contrast to the standard treatment in use before computer tomographic and magnetic resonance imaging and before the mic...

Analysis of the results of recurrent intracranial meningiomas treated with re-radiosurgery.

Meningioma is the most common intracranial neoplasm, comprising approximately 30% of all primary intracranial tumors (Claus et al., 2005) [1]. Treatment options include observation, microsurgical rese...

Neurocognitive function surrounding the resection of frontal WHO grade I meningiomas: A prospective matched-control study.

Patients suffering from intracranial meningiomas may suffer from neurocognitive dysfunctions in specific cognitive domains depending on tumor location and size. The literature on the cognitive functio...

Analysis the causes of radiosurgical failure in intracranial meningiomas treated with radiosurgery.

Surgical resection is a primary indication for intracranial meningioma. Radiosurgery is also an excellent treatment modality for postoperative residual tumors, or tumors in high-risk locations, such a...

Clinical Trials [2610 Associated Clinical Trials listed on BioPortfolio]

Multisession Radiosurgery in Large Meningiomas

This is a prospective observational trial consisting of robotic multisession radiosurgery (CyberKnife ®) for large and medium size and/or located at critical site benign intracranial meni...

Oncological Care for Patients With Meningioma

Meningiomas with malignant components include grade II meningiomas (GIIM, the most common ones) and grade III meningiomas (GIIIM). They represent 5-35% of all meningiomas. Histological dia...

Interferon Alfa in Treating Patients With Recurrent Unresectable Meningiomas and Malignant Meningiomas

RATIONALE: Interferon alfa may interfere with the growth of cancer cells. PURPOSE: Phase II trial to study the effectiveness of interferon alfa in treating patients with recurrent unresec...

Cavernous Sinus Dissection and Bleeding in Meningiomas

The blood loss will be compared in middle fossa meningiomas which will receive pealing of the outer layer of the lateral wall of the cavernous sinus and those which will not revive pealing...

AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas

The goal of this clinical research study is to learn if the study drug AZD2014 can shrink growing or symptomatic meningiomas.

Medical and Biotech [MESH] Definitions

An autosomal dominant disorder characterized by a high incidence of bilateral acoustic neuromas as well as schwannomas (NEURILEMMOMA) of other cranial and peripheral nerves, and other benign intracranial tumors including meningiomas, ependymomas, spinal neurofibromas, and gliomas. The disease has been linked to mutations of the NF2 gene (GENES, NEUROFIBROMATOSIS 2) on chromosome 22 (22q12) and usually presents clinically in the first or second decade of life.

Use of reflected ultrasound in the diagnosis of intracranial pathologic processes.

Methods to determine in patients the nature of a disease or disorder at its early stage of progression. Generally, early diagnosis improves PROGNOSIS and TREATMENT OUTCOME.

A well-circumscribed mass composed of tuberculous granulation tissue that may occur in the cerebral hemispheres, cerebellum, brain stem, or perimeningeal spaces. Multiple lesions are quite common. Management of intracranial manifestations vary with lesion site. Intracranial tuberculomas may be associated with SEIZURES, focal neurologic deficits, and INTRACRANIAL HYPERTENSION. Spinal cord tuberculomas may be associated with localized or radicular pain, weakness, sensory loss, and incontinence. Tuberculomas may arise as OPPORTUNISTIC INFECTIONS, but also occur in immunocompetent individuals.

A system for classifying patient care by relating common characteristics such as diagnosis, treatment, and age to an expected consumption of hospital resources and length of stay. Its purpose is to provide a framework for specifying case mix and to reduce hospital costs and reimbursements and it forms the cornerstone of the prospective payment system.

Quick Search
DeepDyve research library